The combination of CAd-VECPDL1 with HER2-targeted CAR T cells showed enhanced antitumor activity compared to treatment with HER2-targeted CAR T cells alone, HER2-targeted CAR T cells plus unarmed OAd and even anti-PD-L1 blocking antibody plus HER2-targeted CAR T cells in a HER2 prostate cancer xenograft model. The gene discussed is ERBB2; the disease is prostate cancer.